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http:WHAT THIS PAPER ADDS
This study adds to the data regarding open revascularization surgery for CLI using an alternative vein conduit.Objectives: The value of alternative autogenous venous conduits for treating critical limb ischaemia (CLI) with
infragenicular bypass surgery is well established. In this study, the results of using arm veins as alternative
conduits for treating CLI over a 15-year period have been evaluated.
Methods: This was a retrospective study. Between 1991 and 2005. 120 infragenicular bypasses using arm vein
conduits (AVCs) were performed in 120 patients. CLI was the main indication (87.5%) for the procedures. The
indications for using arm veins were inadequacy or absence of the ipsilateral greater saphenous vein (GSV).
Survival, limb salvage, and patency rates were calculated using the KaplaneMeier method.
Results: There was a predominance of male gender (65%), and the group mean age was 68.1  8.3 years. The
mean follow-up period was 29.6  26.3 months. The operative mortality (30 days) rate was 7.5%. The main
alternative conduit was non-spliced cephalic vein (37.5%). Composite grafts included GSV þ AVC (45.2%),
AVC þ AVC (43.3%) and small saphenous vein þ AVC (11.5%). The 5-year primary and secondary patency (SP)
rates were 45.2  5.6% and 56.5  5.0%, respectively. The 5-year SP rate was greatest when using non-spliced
cephalic vein (65.8  7.6%), but there was no difference in cumulative patency between spliced and non-spliced
veins (49.5  8.0% vs. 61.2  6.4%; p ¼ 0.501). The 5-year limb salvage and survival rates were 70.6  5.9% and
59.6  5.8%, respectively.
Conclusions: The favourable long term results of secondary patency and limb salvage rates encourage the use of
arm veins as alternative conduits for infragenicular bypass surgery.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The use of an arm vein as an alternative conduit to the great
saphenous vein (GSV) for infrainguinal bypass surgery, espe-
cially to infragenicular arteries, was ﬁrst proposed by Kakkar
in 1969,1 who demonstrated that the wall of the cephalic vein
can resist arterial pressure and is long enough to reach the
distal popliteal artery. If the GSV of the affected limb is un-
available because it is absent or inadequate for infrainguinal
bypass, some surgeons resort to using the contralateral
GSV,2,3 while others spare this vein and use an arm vein
conduit (AVC)4,5 as the all-autologous policy. Despite a lack of
consensus regarding the best technical approach, this policy
has led to renewed interest in AVC and has led to improved
technical skills for arterial reconstruction procedures6,7 and to
better overall outcomes in large surgical series.5,6,8rresponding author. G. Sandri, Hospital do Servidor Publico Estadual
Paulo, San Paulo, Brazil.
il address: dr_sandri@hotmail.com (G.A. Sandri).
-5884/$ e see front matter  2014 European Society for Vascular
. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2014.01.019Although prosthetic grafts have been used for below-
knee arterial bypass procedures, Veith et al.9 reported
poor patency of prosthetic grafts compared with the GSV in
a randomized clinical trial. Recent developments in pros-
thetic grafts, including the introduction of heparin-coated
PTFE, have improved the cumulative patency and limb
salvage rates.10 However, Arvela et al.11 reported that arm
veins, even when spliced, are superior to prosthetic grafts in
terms of secondary patency and limb salvage for treating
critical limb ischaemia (CLI). Therefore, the aim of the cur-
rent study was to evaluate the long-term outcome of using
an AVC as an alternative conduit in infragenicular bypass
procedures over a 15-year period in this department.
MATERIALS AND METHODS
Study design
Between 1991 and 2005, 1,634 infrainguinal bypass pro-
cedures were performed in the Vascular Surgery Depart-
ment of the Hospital do Servidor Público Estadual de São
Paulo, Brazil. These procedures included 120 (7.3%) infra-
genicular bypass procedures using arm veins. During the
Table 1. Clinical and demographic characteristics.
Age 68.1  8.3
Male gender 78 (65.0%)
Systemic hypertension 82 (68.3%)
Diabetes mellitus 82 (68.3%)
Smoking 67 (56%)
Coronary heart disease 12 (10.0%)
Critical limb ischemia 105 (87.5%)
Tissue loss 84 (70.0%)
Rest pain 21 (17.5%)
Composite substitute 53 (44.2%)
Previous ipsilateral bypass graft 55 (45.8%)
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graft were performed. Patients were prospectively followed
up according to a speciﬁc protocol advocated by the Society
for Vascular Surgery Joint Council.12 Data were retrospec-
tively collected from the patient’s medical records. All pa-
tients and relatives were informed of the proposed
procedure, including the harvesting of arm veins. The cur-
rent study was approved by the local ethics committee.
Patient selection
The majority (87.5%) of patients underwent revasculariza-
tion to treat CLI. Other reasons for treatment were salvage
of a failed previously constructed arterial bypass graft (10%)
and popliteal artery aneurysm (2.5%).
All patients admitted to the department with a diagnosis
of chronic CLI are considered candidates for peripheral
revascularization of the affected limb. The ipsilateral GSV is
the conduit of choice if it is present and adequate. Since
1998, all autogenous conduits have been assessed by
duplex ultrasonography with the following criteria assessed:
available length, diameter (3 mm), absence of a thickened
wall (focal or diffuse), and preserved compressibility. The
GSV was deemed inadequate for use as the primary conduit
if any of these criteria were not fulﬁlled. In this situation,
upper limb veins were assessed as alternative primary
conduits using the same criteria as for GSV. After selecting
the conduit, the vein was safeguarded by obtaining venous
access through one of the internal jugular veins and looking
for any signs of previous venous puncture in the chosen
limb.
Surgical technique
The non-reversed translocated graft method was used in all
patients, with valve lysis achieved using aMills valvulotome13
after completing the proximal anastomosis and removing the
clamps. Valve lysis is routinely performed, even for the
inherently reversed segment of the basilicecephalic loop, to
maintain physiologic ﬂow phasicity. A second surgical team
generally harvested the AVC simultaneously with achieving
arterial access and creating the tunnel for the graft. General
anaesthesia was used for all patients except in high surgical
risk patients who received regional blockade with no com-
plications. A single incision was made over the anatomic vein
trajectory. AVC compliance is greater than that of GSV, and
the tributaries must be ligated>1 mm from the main venous
trunk to avoid focal stenosis after removing the arterial
clamps. Compressive bandages were applied after closing
the incision.
Follow-up
All patients were treated with aspirin (100 mg/day) peri-
operatively and after discharge. Regular follow up included
the following bypass graft assessments: signs and symptoms
questionnaire, physical examination with pulse palpation
and measurement of the ankleebrachial index (ABI), and
laboratory tests. If possible, duplex scan surveillance was
performed 1 month after surgery, every 6 months for 2years, and yearly thereafter. A duplex scan was always
performed if any change was noted at the clinical exami-
nation (e.g., reduction in pulse or ABI). If any haemody-
namically signiﬁcant stenosis14 was detected at the
anastomotic sites or in the graft body, the patient was
admitted for digital angiography to plan an assisted primary
patency procedure.Statistical analysis
Patency, limb salvage, and survival rates were analysed
using the KaplaneMeier method and were compared with
log-rank tests using the Statistical Package for Social Sci-
ences version 13.0 (SPSS Inc., Cary, NC, USA). A standard
error of .1 to was considered to be acceptable. A p value
.05 was considered to indicate statistical signiﬁcance in
comparisons between variables.RESULTS
The study group consisted of 78 men and 42 women, with a
mean  standard deviation age of 68.1  8.3 years. The
most prevalent risk factors were systemic hypertension
(68.3%), diabetes mellitus (68.3%), smoking (55.8%), and
heart disease (10.4%) (Table 1).
Indications for using arm veins included the absence of
an ipsilateral GSV in 67 patients, inadequate GSV in 46
patients, and was unknown in seven patients. Single-
segment veins were used in 67 patients, including ce-
phalic vein in 45 patients, basilic vein in 17 patients, and a
basilicecephalic loop in ﬁve patients. Spliced veins were
used in 53 patients with a composition as following: GSV
plus arm vein (24e45.2%); cephalic plus basilic vein (23e
43.3%), and saphenous vein plus arm vein (6e11.5%). Pri-
mary and secondary revascularization with AVC was per-
formed in 65 (54.2%) and 55 (45.8%) patients, respectively.
The proximal and distal anastomoses are listed in Table 2.
The operative mortality rate (30 days) was 7.5% and
there was no association with any condition, including
coronary heart disease and age >80 years. The main sur-
gical complications included early graft occlusion (9e7.5%)
and one graft infection, which was treated by ligature and
major amputation.
The mean follow-up period was 29.6  26.3 months.
During the follow-up period, 54 and 55 bypass grafts were
occluded at 3 and 5 years, respectively, yielding primary
Table 2. Proximal and distal anastomoses.
Proximal anastomoses
Common iliac 1 0.8
External iliac 7 5.8
Common femoral 25 20.8
Superﬁcial femoral 39 32.5
Deep femoral 15 12.5
Popliteal above knee 5 4.2
Popliteal below knee 5 4.2
Anterior tibial 1 0.8
Previous graft 22 18.3
Distal anastomoses
Popliteal BK 28 23.3
Tibioperoneal trunk 3 2.5
Anterior tibial 25 20.8
Posterior tibial 14 11.7
Peroneal 21 17.5
Dorsalis pedis 12 10.0
Common plantar 4 3.3
Genicular 3 2.5
Previous graft 8 6.7
Lateral tarsal 1 0.8
Other foot artery 1 0.8
Figure 1. Survival curves for limb salvage and patencies (SE <10%
for the entire period). Note. APP ¼ assisted primary patency;
LS ¼ limb salvage; PP ¼ primary patency; SP ¼ secondary patency.
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years, respectively. Surgical revision was performed in seven
cases, yielding a secondary patency rate of 56.5  5.0% at
both 3 and 5 years. All of these salvage procedures were
performed using an interposition bypass with an autoge-
nous conduit. Six patients developed mild AVC graft dila-
tation, but no graft aneurysms were found.
By univariate analysis, only graft occlusion was associated
with limb loss (odds ratio ¼ 22.39; conﬁdence interval 6.9e
72.5; p < .001). Major amputation was necessary in 17 and
21 patients at 3 and 5 years, respectively. Therefore, the
cumulative limb salvage rates were 80  4.4% and
70.6  5.9% at 3 and 5 years, respectively. The survival rates
were 72.8  4.3% and 59.6  5.8% at 3 and 5 years,
respectively. The patency, limb salvage, and survival rates
are presented in Fig. 1.
In subgroup analysis of comorbidities and technical var-
iants, there were no statistically signiﬁcant differences in
secondary patency or limb salvage rates, as shown in
Table 3. There were no signiﬁcant differences in secondary
patency rate at 5 years between spliced and non-spliced
conduits (49.5  8.0% and 61.2  6.4%, respectively;
p ¼ .50). The best results were achieved when using a single
segment of the cephalic vein, with a 5-year secondary
patency rate of 65.8  7.6%.DISCUSSION
Although endovascular procedures play an important role in
treating CLI and have gained widespread interest over the
last two decades, infrainguinal surgical reconstructions are
still needed for limb salvage. Numerous studies have re-
ported satisfactory outcomes using an AVC for treating CLI
without increasing the operative time, because the AVC can
be harvested simultaneously by a second operative teamwhile the inﬂow and outﬂow arteries are being dissected.
Faries et al.8 published a large series of 520 AVC bypass
grafts, and reported encouraging results for patency (57.5%)
and limb salvage (71.5%) at 5 years.
The rate of GSV utilization in infrainguinal bypass re-
vascularizations was reported to be 66% by Taylor et al.,15
84% by Abu-Zamzam et al.,16 and 69% in our series of pa-
tients. The availability of an AVC and its use as an alterna-
tive to the GSV in this series is somewhat lower because
multiple venous punctures had been performed during
previous hospital admissions. A policy was adopted to
protect the upper limbs from any kind of puncture in pa-
tients admitted with CLI who had already undergone arte-
rial bypass surgery. Regarding the evaluation of arm vein
quality, Vauclair et al.17 reported a detailed protocol for arm
vein scanning, which included the application of a proximal
tourniquet similar to the protocol used in this department.
Veins with any of the following were deﬁned as being of
poor quality: diameter <2.5 mm, thrombosis, aneurysm,
focal wall thickening, and the presence of intraluminal
webs.17 The 5-year outcomes in this series were satisfactory
in terms of the cumulative patency (56.6%) and limb
salvage (70.6%) rates, and the results are consistent with
those of other studies that demonstrated encouraging
outcomes using an AVC, especially for non-spliced cephalic
vein (65.8%), which were similar to those of GSV.18
The results of some arm vein series are summarized in
Table 4.
Although these results were obtained in a prospective
non-randomized study, the superiority of the 3-year patency
of GSV compared with arm vein (68% vs. 57%) and limb
salvage (81% vs. 57%) rates has been conﬁrmed.19 In a
retrospective review of 1,109 consecutive infrainguinal by-
passes, Arvela et al.20 evaluated the outcome of using an
Table 3. Comorbidities and technical variants.
Factor Secondary patency Limb salvage
N Failure
per 100
individuals/month
Failure
ratio
p N Failure per 100
individuals/month
Failure
ratio
p
Gender Female 42 2.233 1 .40 42 0.747 1 .65
Male 78 1.457 0.65 78 0.670 0.9
Hypertension No 38 1.528 0.86 .98 38 0.621 0.85 .97
Yes 82 1.776 1 82 0.727 1
Diabetes No 37 1.266 0.65 .41 37 0.606 0.81 .77
Yes 82 1.952 1 82 0.747 1
Smoking No 52 1.846 1 .71 52 0.645 0.88 .89
Yes 67 1.641 0.89 67 0.734 1
Symptom Rest pain 21 1.626 0.84 .82 21 3.048 0.92 .71
Necrosis 84 1.942 1 84 3.327 1
Distal artery Popliteal 28 1.902 1 .33 28 1.082 1 .09
Infrapopliteal 92 1.607 0.84 92 0.551 0.51
Composite
vein
No 67 1.463 0.72 .50 67 0.593 0.73 .57
Yes 53 2.022 1 53 0.815 1
Previous
ipsilateral
bypass
No 62 1.829 1 .78 62 0.808 1 .52
Yes 55 1.623 0.89 55 0.586 0.73
612 F. Brochado Neto et al.arm vein and a small saphenous vein (SSV) compared with
the GSV. The use of alternative conduits was an indepen-
dent risk factor for graft stenosis and graft occlusion. Arvela
et al. also reported that the revision rate was higher in the
non-GSV group than in the GSV group (18% vs. 12%;
p ¼ .007). Compared with other autogenous conduits, the
AVC has advantages over the SSV because of its length,
which allows for longer bypass grafts capable of reaching
the distal arteries. The SSV is commonly used for short
bypass grafts or as part of a spliced vein graft, because of its
limited length.3,23
In a prospective study of 42 lower extremity arm vein
bypasses, Chalmers et al.24 reported a high incidence of
graft revision, which was attributed to the use of composite
grafts. However, their use of intensive duplex surveillance
identiﬁed these pre-occlusive lesions, which were subjected
to primary assisted intervention with extension vein grafts.
These actions were associated with an increase in the 2-
year primary patency rate of 46% to a secondary patency
rate of 85%. Although data regarding the location of the
graft stenosis in arm vein revisions are not available, the
majority of these lesions were unsuitable for angioplastyTable 4. Arm vein series.
First author year N Study design
Faries et al.8 2000 520 Prospective
Brochado-Neto et al.19 2001 35 Prospective
Varcoe et al.21 2007 35 Prospective
Arvela et al.11 2010 130 Retrospective
Vauclair et al.17 2012 56 Retrospective
Robinson et al.22 2013 35 Retrospective
Current study 120 Retrospective
N ¼ number of patients enrolled; SP ¼ secondary patency; LS ¼ limbbecause of the extensive length of lesions. The percuta-
neous approach has been reserved for focal stenosis.
Direct comparison of the performance of AVC grafts in
the present study and GSV grafts in earlier studies is subject
to some bias because of the large number of secondary
revascularizations (47%) in this series. Another possible bias
is the heterogeneity of the arm veins used in this series and
the preference for the cephalic vein over the basilic or
spliced veins. Although not statistically signiﬁcant, the
present results favour the cephalic vein over basilic or
spliced veins, probably because of the small number of
patients in each subgroup, as previously described.25
Some authors have reported that one of the main dis-
advantages of arm veins is graft dilatation.26,27 Mild dila-
tation in an AVC was observed in six patients in the present
series, and no venous aneurysms were detected after 5
years of follow-up, perhaps because of the greater
compliance of these conduits.
If the ipsilateral GSV is not available, the preference is for
an adequate AVC instead of the contralateral GSV. In cur-
rent practice, we have observed that around 25% of the
patients need contralateral GSV harvesting for lower limbSP LS SV
5 y ¼ 57.5% 5 y ¼ 71.5% 4 y ¼ 54%
3 y ¼ 57% 4 y ¼ 57% 4 y ¼ 62%
5 y ¼ 76% 5 y ¼ 91% 5 y ¼ 65%
3 y ¼ 57.4% 3 y ¼ 75% 3 y ¼ 58.8%
3 y ¼ 88% 3 y ¼ 88% 3 y ¼ 50%
5 y ¼ 49% 5 y ¼ 76% 5 y ¼ 49%
5 y ¼ 56.5% 5 y ¼ 70.6 5 y ¼ 59.6
salvage; SV ¼ survival; y ¼ years.
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studies, the necessity of contralateral GSV harvesting varies
between 11% and 30%.3,5,15,16,28 This is probably related to
the naturally safe anatomical location of the GSV, whereas
the superﬁcial AVC is commonly exposed to traumatic injury
(e.g. venous puncture for clinical purposes) and often de-
velops focal phlebitis and ﬁbrosis that limit its use in future
interventions.
The AVC has two major advantages over prosthetic
grafts: (a) higher long-term patency and limb salvage rates
for below-knee bypass grafts, and (b) a lower infection
rate.29 In a retrospective study of 290 bypasses, Arvela
et al.11 reported that the 3-year secondary patency and limb
salvage rates were better for arm veins than for prosthetic
grafts in infrapopliteal bypasses. Faries et al.30 conducted a
study where composite grafts using prosthetic grafts and
autogenous veins where compared with arm veins. Even
when multiple segments of arm veins were used, the cu-
mulative patency rate was better than that of prosthetic
grafts (70.7% vs. 44.9%; p < .001). In a multicentre registry,
Pulli et al.10 reported good mid-term results with heparin-
bonded prosthesis, achieving a 3-year secondary patency
and limb salvage of 70% and 83%, respectively.
Holzenbein et al.31 reported good outcomes using the
basilicecephalic loop, a technique that allows the surgeon
to lengthen the graft without needing to splice the vein. In
this series the technique was used in ﬁve cases. Non-spliced
basilic vein had satisfactory outcomes in this series (55.6%).
However, a previous paper3 speciﬁcally analysed the out-
comes when it was used as an infrapopliteal bypass graft,
and the authors reported it showed limited success when
used as a spliced conduit with the cephalic vein.
In this vascular surgery department, AVC is used as the
conduit of choice if the ipsilateral GSV is absent or inade-
quate. The surgical technique demands extra care in
handling the AVC while harvesting and implanting the
bypass graft because it has a more delicate wall compared
with the GSV. However, the type of anaesthesia is consid-
ered a disadvantage because of the large number of sec-
ondary procedures performed (47%) and because high-risk
patients, who are unﬁt for general anaesthesia, require
regional block for the upper limb and spinal block for the
lower limb. Despite these considerations, AVC had good
outcomes in the treatment of CLI, clearly demonstrating its
beneﬁts as an alternative arterial substitute. Patients with
rest pain or ischaemic gangrene have a major amputation
rate of 65% and a 1-year mortality rate of 45% if left un-
treated.32,33 These issues justify efforts to offer these pa-
tients the best surgical treatment. Currently high-risk
surgical patients and those lacking an appropriate autolo-
gous vein have been treated by an endovascular approach
or infrapopliteal bypasses with prosthetic graft.
In conclusion, in an autogenous only policy for treating
CLI, AVCs may offer 56.5% secondary patency and 70.6%
limb salvage rates at 5 years for infragenicular disease. The
secondary patency rate following the use of a non-spliced
cephalic vein in our study was similar to that reported for
the GSV in earlier studies.CONFLICT OF INTEREST
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